Spagnolo Primavera A, Ramchandani Vijay A, Schwandt Melanie L, Zhang Lishu, Blaine Sara K, Usala Julie M, Diamond Kristie A, Phillips Monte J, George David T, Momenan Reza, Heilig Markus
Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland.
Alcohol Clin Exp Res. 2014 Dec;38(12):3024-32. doi: 10.1111/acer.12581.
Positively reinforcing properties of alcohol are in part mediated by activation of the ventral striatum (VS). Alcohol-induced release of endogenous opioids is thought to contribute to this response. Preclinical studies show that the opioid antagonist naltrexone (NTX) can block this cascade, but its ability to do so in treatment-seeking alcoholics has not been examined. Our objective was to study the effects of NTX on alcohol-induced VS activation and on amygdala response to affective stimuli in treatment-seeking alcohol-dependent inpatients.
Sixty-three treatment-seeking alcoholics were randomized to receive NTX (50 mg) or placebo (PLC) daily. On Day 7, participants underwent an alcohol cue reactivity session, and craving was measured using the Penn Alcohol Craving Scale. On Day 9, participants received a saline infusion followed by an alcohol infusion and also viewed affective stimuli in a magnetic resonance scanner.
Irrespective of medication treatment condition, the alcohol infusion did not activate the VS in the alcohol-dependent patients. Unexpectedly, VS activation was greater in NTX treated patients than in the PLC group. NTX treated patients also reported increased craving in response to alcohol cue exposure, and increased subjective response to alcohol ("high" and "intoxicated") compared to PLC subjects. No significant effects of alcohol infusion on brain response to affective stimuli were in the NTX or PLC groups.
Unlike previous findings in social drinkers, a moderate level of intoxication did not activate the VS in treatment-seeking alcoholics. This is likely to reflect tolerance to the positively reinforcing properties of alcohol in this clinical population. Our findings may help explain the efficacy of NTX to reduce heavy drinking, but not to maintain abstinence.
酒精的正性强化特性部分是由腹侧纹状体(VS)的激活介导的。酒精诱导内源性阿片类物质的释放被认为有助于这种反应。临床前研究表明,阿片类拮抗剂纳曲酮(NTX)可以阻断这一过程,但尚未研究其在寻求治疗的酗酒者中的作用。我们的目的是研究NTX对寻求治疗的酒精依赖住院患者中酒精诱导的VS激活以及杏仁核对情感刺激的反应的影响。
63名寻求治疗的酗酒者被随机分为每天接受NTX(50毫克)或安慰剂(PLC)治疗。在第7天,参与者进行酒精线索反应测试,并使用宾夕法尼亚酒精渴望量表测量渴望程度。在第9天,参与者接受生理盐水输注,随后接受酒精输注,并在磁共振扫描仪中观看情感刺激。
无论药物治疗情况如何,酒精输注均未激活酒精依赖患者的VS。出乎意料的是,接受NTX治疗的患者的VS激活程度高于PLC组。与PLC组相比,接受NTX治疗的患者在接触酒精线索后也报告渴望增加,并且对酒精的主观反应(“兴奋”和“陶醉”)增强。在NTX或PLC组中,酒精输注对大脑对情感刺激的反应没有显著影响。
与先前在社交饮酒者中的发现不同,适度的醉酒状态并未激活寻求治疗的酗酒者的VS。这可能反映了该临床人群对酒精正性强化特性的耐受性。我们的研究结果可能有助于解释NTX减少大量饮酒但不能维持戒酒的疗效。